CD49b, CD87, and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent Normal Fibroblasts in Murine Tumor Models

被引:19
作者
Agorku, David J. [1 ,2 ]
Langhammer, Anne [1 ]
Heider, Ute [1 ]
Wild, Stefan [1 ]
Bosio, Andreas [1 ]
Hardt, Olaf [1 ]
机构
[1] Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
[2] HAN Univ Appl Sci, HAN Master Programmes, Nijmegen, Netherlands
关键词
cancer-associated fibroblasts; normal fibroblasts; subcutaneous 4T1 mouse tumor model; subcutaneous CT26.WT mouse tumor model; CD39; CD87; CD49b; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; FAS LIGAND; CELLS; EXPRESSION; HETEROGENEITY; METASTASIS; RESISTANCE; ANTIGEN; SYSTEM;
D O I
10.3389/fonc.2019.00716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibroblasts are thought to be key players in the tumor microenvironment. Means to identify and isolate fibroblasts as well as an understanding of their cancer-specific features are essential to dissect their role in tumor biology. To date, the identification of cancer-associated fibroblasts is widely based on generic markers for activated fibroblasts in combination with their origin in tumor tissue. This study was focused on a deep characterization of the cell surface marker profile of cancer-associated fibroblasts in widely used mouse tumor models and defining aberrant expression profiles by comparing them to their healthy counterparts. We established a generic workflow to isolate healthy and cancer-associated fibroblasts from solid tissues, thereby reducing bias, and background noise introduced by non-target cells. We identified CD87, CD44, CD49b, CD95, and Ly-6C as cancer-associated fibroblast cell surface markers, while CD39 was identified to mark normal fibroblasts from healthy tissues. In addition, we found a functional association of most cancer-related fibroblast markers to proliferation and a systemic upregulation of CD87, and CD49b in tumor-bearing mice, even in non-affected tissues. These novel markers will facilitate the characterization of fibroblasts and shed further light in their functions and implication in cancer progression.
引用
收藏
页数:13
相关论文
共 76 条
[1]   The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets [J].
Allard, Bertrand ;
Longhi, Maria Serena ;
Robson, Simon C. ;
Stagg, John .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :121-144
[2]   Tumor promoting effects of CD95 signaling in chemoresistant cells [J].
Ametller, Elisabet ;
Garcia-Recio, Susana ;
Costamagna, Domizziana ;
Mayordomo, Cristina ;
Fernandez-Nogueira, Patricia ;
Carbo, Neus ;
Maria Pastor-Arroyo, Eva ;
Gascon, Pedro ;
Almendro, Vanessa .
MOLECULAR CANCER, 2010, 9
[3]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[4]  
2-Z
[5]   CD39 and CD73 in immunity and inflammation [J].
Antonioli, Luca ;
Pacher, Pal ;
Vizi, E. Sylvester ;
Hasko, Gyoergy .
TRENDS IN MOLECULAR MEDICINE, 2013, 19 (06) :355-367
[6]  
ARNDT R, 1977, IMMUNOLOGY, V33, P101
[7]   CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells [J].
Barnhart, BC ;
Legembre, P ;
Pietras, E ;
Bubici, C ;
Franzoso, G ;
Peter, ME .
EMBO JOURNAL, 2004, 23 (15) :3175-3185
[8]  
Bernard V, 2018, BIORXIV, DOI [10. 1101/306134, DOI 10.1101/306134]
[9]   IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma [J].
Biffi, Giulia ;
Oni, Tobiloba E. ;
Spielman, Benjamin ;
Hao, Yuan ;
Elyada, Ela ;
Park, Youngkyu ;
Preall, Jonathan ;
Tuveson, David A. .
CANCER DISCOVERY, 2019, 9 (02) :282-301
[10]   Expression of ectonucleotidase CD39 by Foxp3+ Treg cells:: hydrolysis of extracellular ATP and immune suppression [J].
Borsellino, Giovanna ;
Kleinewietfeld, Markus ;
Di Mitri, Diletta ;
Sternjak, Alexander ;
Diamantini, Adamo ;
Giometto, Raffaella ;
Hoepner, Sabine ;
Centonze, Diego ;
Bernardi, Giorgio ;
Dell'Acqua, Maria Luisa ;
Rossini, Paolo Maria ;
Battistini, Luca ;
Rotzschke, Olaf ;
Falk, Kirsten .
BLOOD, 2007, 110 (04) :1225-1232